| |||
| 7 FEBRUARY 2012 Application Notes bring you the latest information about innovative tools and technologies and their applications in the lab. We hope that you will find this service useful and informative and encourage you to sign up for future Updates to ensure that you never miss one! | ||||||||||||
| ||||||||||||
![]() | Novel Approach in Identification of Substrates for Ligases: Protein Microarrays www.lifesensors.com > Dedicated to providing pioneering reagents as well as proteomic service solutions to all questions ubiquitin related, LifeSensors scientists can turn questions into answers. Perhaps no question is more commonly asked of the ubiquitome than “what are the substrates of my E3?”. A combination of protein microarray expertise and novel ubiquitin research reagents makes LifeSensors uniquely qualified to get you those answers. | |||
![]() | Generation of cell lines using Epstein-Barr Virus (EBV) transformation of small volumes of cryo-preserved whole blood and the use of bench-top flow cytometry to achieve high and reproducible success rates www.hpacultures.org.uk > ECACC has developed a procedure for the generation of lymphoblastoid cell lines (LCLs) by the direct EBV transformation of small amounts (800µl) of cryo-preserved whole blood eliminating any requirement for prior separation of peripheral blood lymphocytes (PBLs). The ability to directly transform frozen whole blood avoids the cost of separating and storing PBLs while retaining the option to make a cell line at any time from all or a subset of the collection. Consistent transformation success rates of over 90% have been achieved using bench-top flow cytometry to track lymphoblastoid proliferation from source blood that has been cryo-preserved for more than four years. | |||
![]() | Antigen specific antibody-producing clones selected by isotypes using the CellCelector™ system www.biosys-intl.com > BioSystems International (BSI) discovers novel biomarkers by performing monoclonal antibody-proteomics profiling for specific diseases. Recently, we have reported the discovery of lung cancer associated biomarkers with potential for clinical applications based on the technology. We have screened the biomarkers in a sandwich assay using monoclonal antibodies (mAbs) directed against two non-overlapping epitopes. These mAbs including an anti-leucine-rich alpha-2-glycoprotein-1 (anti-LRG1), capable to measure the differential protein level in plasma, were generated and isolated from an internal large hybridoma collection. | |||
![]() | EndoLISA®: a novel and reliable method for endotoxin detection www.hyglos.de > A new test for the sensitive detection of endotoxin has been developed, based on a lipopolysaccharide-selective, precoated microplate and a factor C–based detection reagent and presented in a complete kit format. The selective capture of lipopolysaccharide (LPS) is achieved using a phage-derived receptor protein exhibiting high affinity and high specificity for the conserved core region of LPS. After binding of sample-LPS to the microplate as the first stage of the assay, the original sample matrix is washed off, thereby eliminating potentially interfering components. In the second stage of the assay, LPS is detected by factor C in a process whereby the principal receptor of the Limulus amoebocyte coagulation cascade reacts with a fluorescence substrate. The new endotoxin test EndoLISA has a detection range from 0.05 EU/ml up to 500 EU/ml. | |||
| Expresso® Cloning and Expression Systems: Expressioneering™ Technology streamlines recombinant protein expression< www.lucigen.com/ > The Expresso® Cloning and Expression Systems use Expressioneering™ Technology to dramatically increase the speed and efficiency of target gene cloning and soluble protein expression in Escherichia coli. With Expressioneering, PCR products are cloned instantly and directionally into preprocessed expression vectors without sample cleanup or enzyme treatment. The Expresso Rhamnose System is a single-host system ideal for high throughput, allowing cloning in an effortless afternoon and recombinant protein expression the next day. | ||||
| Ribo-Zero Gold Kit: improved RNA-seq results after removal of cytoplasmic and mitochondrial ribosomal RNA www.epibio.com > Ribosomal RNA (rRNA) constitutes the majority (>98%) of total RNA preparations. To avoid wasting sequencing reads, it is necessary to remove this abundant RNA before preparing RNA libraries for deep sequencing. We previously developed Ribo-Zero™ technology for cytoplasmic rRNA removal from intact and degraded RNA. Here, we describe the Ribo-Zero Gold Kit: an improvement to the original Ribo-Zero method that allows removal of mitochondrial as well as cytoplasmic rRNA from total RNA preparations. | ||||
Application Notes are supplied by commercial companies. The Nature Publishing Group does not endorse any of the products or services advertised here. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices:London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston |
![]() |






No comments:
Post a Comment